 Canadian granting agency MITACS commits to three years of funding for the projects second stage to optimize certain proprietary microcarrier technologies for use in RepliCels cell therapy manufacturing RepliCel signs an Option to License agreement related to a filed US patent application VANCOUVER, BC ACCESSWIRE September 16, 2021 RepliCel Life Sciences Inc. OTCQB:REPCFTSXV:RPFRA:P6P2 RepliCel or the Company, a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that the first-stage of a research project with the University of Victoria Centre for Biomedical Engineering UVic has led to significant milestones in terms of technology advancements, patent filings, grant funding, and a license option agreement. As a result of the innovations coming out of the collaboration to-date, RepliCel has signed a Technology Evaluation and Option to License agreement pertaining to a patent filed with the US Patent Office USPTO on multifunctional microcarriers with thermal-responsive biomaterials coatings. 